[{"id":"d3130d99-194c-46a1-903b-9c16e7da7d5d","acronym":"LOOMIS","url":"https://clinicaltrials.gov/study/NCT03951220","created_at":"2025-08-23T13:30:42.676Z","updated_at":"2025-08-23T13:30:42.676Z","phase":"","brief_title":"The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss","source_id_and_acronym":"NCT03951220 - LOOMIS","lead_sponsor":"Oxford University Hospitals NHS Trust","biomarkers":" DKK1","pipe":"","alterations":" ","tags":["DKK1"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 03/29/2018","start_date":" 03/29/2018","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2025-08-19"},{"id":"a18b55f5-28ba-44e3-9d03-4d9885a2070f","acronym":"DisTinGuish","url":"https://clinicaltrials.gov/study/NCT04363801","created_at":"2021-01-18T21:05:30.406Z","updated_at":"2024-07-02T16:35:22.721Z","phase":"Phase 2","brief_title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","source_id_and_acronym":"NCT04363801 - DisTinGuish","lead_sponsor":"Leap Therapeutics, Inc.","biomarkers":" PD-L1 • DKK1","pipe":"","alterations":" ","tags":["PD-L1 • DKK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium • sirexatamab (DKN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-22"},{"id":"3c4991de-db64-4065-98be-20d6b4e3f446","acronym":"","url":"https://clinicaltrials.gov/study/NCT03848676","created_at":"2021-01-18T18:59:48.511Z","updated_at":"2024-07-02T16:35:36.215Z","phase":"","brief_title":"Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma","source_id_and_acronym":"NCT03848676","lead_sponsor":"University of Turin, Italy","biomarkers":" CD8 • IL6 • CD38 • CRBN • DKK1 • CD4 • CD55 • CD59","pipe":" | ","alterations":" CD38 expression • CRBN mutation","tags":["CD8 • IL6 • CD38 • CRBN • DKK1 • CD4 • CD55 • CD59"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CRBN mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-09-21"},{"id":"7300e9bc-2738-46d0-acf9-18bff85ed65d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02212262","created_at":"2021-01-18T10:21:42.879Z","updated_at":"2024-07-02T16:35:37.643Z","phase":"","brief_title":"Role of Osteocytes in Myeloma Bone Disease","source_id_and_acronym":"NCT02212262","lead_sponsor":"Attaya Suvannasankha","biomarkers":" DKK1 • FGF23","pipe":"","alterations":" ","tags":["DKK1 • FGF23"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 10/07/2014","start_date":" 10/07/2014","primary_txt":" Primary completion: 02/05/2022","primary_completion_date":" 02/05/2022","study_txt":" Completion: 02/05/2022","study_completion_date":" 02/05/2022","last_update_posted":"2023-09-08"},{"id":"2fc097a4-37bd-40c3-a2ae-b48d95d46516","acronym":"AMBROBiMM","url":"https://clinicaltrials.gov/study/NCT04111809","created_at":"2021-01-18T20:06:15.326Z","updated_at":"2024-07-02T16:36:01.489Z","phase":"","brief_title":"Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care","source_id_and_acronym":"NCT04111809 - AMBROBiMM","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" DKK1","pipe":"","alterations":" ","tags":["DKK1"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2022-11-01"},{"id":"edf53596-6aa6-468f-8663-c4465c482691","acronym":"","url":"https://clinicaltrials.gov/study/NCT02895178","created_at":"2021-01-18T14:12:21.018Z","updated_at":"2024-07-02T16:36:32.226Z","phase":"","brief_title":"Lifestyles Of Health And Sustainability for Breast Cancer Survivors","source_id_and_acronym":"NCT02895178","lead_sponsor":"Wonju Severance Christian Hospital","biomarkers":" CTNNB1 • TNFA • DKK1 • GDF15 • IL10 • FGF21 • IL1B • SFRP1 • BDNF • TNFRSF11B","pipe":"","alterations":" ","tags":["CTNNB1 • TNFA • DKK1 • GDF15 • IL10 • FGF21 • IL1B • SFRP1 • BDNF • TNFRSF11B"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-04-08"},{"id":"bd820042-6238-4d72-9b4f-321defd6fbca","acronym":"POUMOS","url":"https://clinicaltrials.gov/study/NCT02810262","created_at":"2021-01-18T13:46:58.204Z","updated_at":"2024-07-02T16:37:01.031Z","phase":"","brief_title":"Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)","source_id_and_acronym":"NCT02810262 - POUMOS","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" EGFR • BRAF • ALK • DKK1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • DKK1"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-04-02"},{"id":"3ba2c543-7e43-449a-9147-229183bef6af","acronym":"","url":"https://clinicaltrials.gov/study/NCT03756532","created_at":"2021-01-18T18:27:59.801Z","updated_at":"2025-02-26T11:19:08.718Z","phase":"Phase 1b/2a","brief_title":"A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1","source_id_and_acronym":"NCT03756532","lead_sponsor":"New York University School of Medicine","biomarkers":" DKK1","pipe":"","alterations":" ","tags":["DKK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • sirexatamab (DKN-01)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2018-11-28"},{"id":"36cf4d45-d640-4301-9c98-715cbdd5a9d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01852799","created_at":"2021-01-18T08:16:19.638Z","updated_at":"2024-07-02T16:37:08.000Z","phase":"Phase 2","brief_title":"A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma","source_id_and_acronym":"NCT01852799","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" DKK1","pipe":"","alterations":" ","tags":["DKK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • doxorubicin hydrochloride • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 01/01/2017","study_completion_date":" 01/01/2017","last_update_posted":"2018-08-10"},{"id":"549a1ef6-eba8-48b1-bfb4-4b61cafd2aa1","acronym":"REBUILD","url":"https://clinicaltrials.gov/study/NCT03475628","created_at":"2021-01-18T17:07:31.443Z","updated_at":"2024-07-02T16:37:12.839Z","phase":"Phase 2","brief_title":"Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma","source_id_and_acronym":"NCT03475628 - REBUILD","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" DKK1 • CCL3","pipe":"","alterations":" ","tags":["DKK1 • CCL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 57","initiation":"Initiation: 02/21/2018","start_date":" 02/21/2018","primary_txt":" Primary completion: 06/20/2019","primary_completion_date":" 06/20/2019","study_txt":" Completion: 02/20/2020","study_completion_date":" 02/20/2020","last_update_posted":"2018-03-23"},{"id":"038d5b74-27dc-440c-a163-6e66973addbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01286077","created_at":"2021-01-18T05:13:08.526Z","updated_at":"2024-07-02T16:37:31.600Z","phase":"Phase 2","brief_title":"Velcade Consolidation Bone Study","source_id_and_acronym":"NCT01286077","lead_sponsor":"Janssen-Cilag International NV","biomarkers":" DKK1","pipe":"","alterations":" ","tags":["DKK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2016-05-30"}]